MICHAEL ANGELO DE LEON
Physical Therapy at Woodland Dr, Indianapolis, IN
License number
Indiana 040242
Category
Restorative Service Providers
Type
Physical Therapist
Address
Address
7345 Woodland Dr SUITE C, Indianapolis, IN 46278
Phone
(317) 286-2885
(317) 536-3097 (Fax)
(317) 536-3097 (Fax)
Personal information
See more information about MICHAEL ANGELO DE LEON at radaris.comName
Address
Phone
706 W 13Th St, Mishawaka, IN 46544
3151 Sylvania St, Portage, IN 46368
4455 Garrison Chapel Rd, Bloomington, IN 47403
Professional information
See more information about MICHAEL ANGELO DE LEON at trustoria.com
Monomeric Insulin Analog Formulations
Monomeric Insulin Analog Formulations
US Patent:
5650486, Jul 22, 1997
Filed:
Jun 1, 1995
Appl. No.:
8/458150
Inventors:
Michael R. De Felippis - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07K 14625, C07K 1462
US Classification:
530305
Abstract:
The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Monomeric Insulin Analog Formulations
Monomeric Insulin Analog Formulations
US Patent:
5747642, May 5, 1998
Filed:
Jun 1, 1995
Appl. No.:
8/458151
Inventors:
Michael R. De Felippis - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07K 1462
US Classification:
530304
Abstract:
The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Monomeric Insulin Analog Formulations
Monomeric Insulin Analog Formulations
US Patent:
5461031, Oct 24, 1995
Filed:
Jun 16, 1994
Appl. No.:
8/260633
Inventors:
Michael R. De Felippis - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3828, C07K 1462
US Classification:
514 4
Abstract:
The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Monomeric Insulin Analog Formulations
Monomeric Insulin Analog Formulations
US Patent:
5952297, Sep 14, 1999
Filed:
Sep 26, 1997
Appl. No.:
8/938245
Inventors:
Michael R. De Felippis - Indianapolis IN
Bruce H. Frank - Indianapolis IN
Bruce H. Frank - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3828
US Classification:
514 3
Abstract:
The present invention discloses various parenteral pharmaceutical formulations having a protracted effect, which comprise: a sterile aqueous suspension of about 20 U/mL to about 500 U/mL insulin analog, about 5 mg/mL to about 10 mg/mL sodium chloride, about 0. 2 to about 2. 0 mg/mL physiologically acceptable buffer, a zinc ion content of about 0. 07 mg/mL to about 0. 1 mg/mL, and a physiologically acceptable preservative at a pH of about 6. 5 to about 7. 8; such that less than 5% of the analog present in the suspension is in the dissolved state.
Insulin Analog Formulations
Insulin Analog Formulations
US Patent:
5547929, Aug 20, 1996
Filed:
Sep 12, 1994
Appl. No.:
8/304070
Inventors:
James H. Anderson - Carmel IN
Michael R. De Felippis - Indianapolis IN
Bruce H. Frank - Indianapolis IN
Henry A. Havel - Indianapolis IN
Michael R. De Felippis - Indianapolis IN
Bruce H. Frank - Indianapolis IN
Henry A. Havel - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3828
US Classification:
514 3
Abstract:
The present invention discloses various parenteral pharmaceutical formulations, which comprise a mixture of a monomeric insulin analog and insulin-NPH. The analog formulations provide a rapid onset and a prolonged duration of action.